Global stability of equilibria in a two-sex HPV vaccination model

Bulletin of Mathematical Biology

Volumn 70, Issue 3, 2008, Pages 894-909

  Elbasha, Elamin H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Cancer; Endemic equilibrium; Global stability; HPV; HPV disease; Mathematical model; Reproduction number; Vaccine

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; BASIC REPRODUCTION NUMBER; BIOLOGICAL MODEL; FEMALE; HUMAN; IMMUNOLOGY; MALE; PAPILLOMA VIRUS; VIRUS INFECTION;

BASIC REPRODUCTION NUMBER; FEMALE; HUMANS; MALE; MODELS, IMMUNOLOGICAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

HUMAN PAPILLOMAVIRUS;

EID: 41049114695     PISSN: 00928240     EISSN: 15229602     Source Type: Journal    
DOI: 10.1007/s11538-007-9283-0     Document Type: Article

References (43)

1. Anderson, R.M., May, R.M., 1991. Infectious Diseases of Humans: Dynamics and Control. Oxford University Press, Oxford.
2. Baseman, J.G., Koutsky, L.A., 2005. The epidemiology of human papillomavirus infections. J. Clin. Virol. 32, S16-24.
3. Barnabas, R., Garnett, G., 2004. The potential public health impact of vaccines against human papillomavirus. In: Prendiville, Davies (Eds.), The Clinical Handbook of Human Papillomavirus, pp. 61-79. Taylor and Francis, London.
4. Berry, J.M., Palefsky, J.M., 2003. A review of human papillomavirus vaccines: from basic science to clinical trials. Front. Biosci. 8, S333-345.
5. Blower, S., Koelle, K., Mills, J., 2002. Health policy modeling: epidemic control, HIV vaccines, and risky behavior. In: Kaplan, Brookmeyer (Eds.), Quantitative Evaluation of HIV Prevention Programs, pp. 260-289. Yale University Press, New Haven.
6. Bosch, F.X., Lorincz, A., Munoz, N., Meijer, C.J., Shah, K.V., 2002. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55, 244-265.
7. Castillo-Chavez, C., Thieme, H., 1995. Asymptotically autonomous epidemic models. In: O. Arino, D. Axelrod, M. Kimmel, M. Langlais (Eds.), Theory of Epidemics. Mathematical Populations Dynamics: Analysis of Heterogeneity, vol. 1, pp. 33-50. Wuerz.
8. Castillo-Chavez, C., Huang, W., Li, J., 1996. Competitive exclusion in gonorrhea models and other sexually-transmitted diseases. SIAM J. Appl. Math. 56, 494-508.
9. Castillo-Chavez, C., Huang, W., Li, J., 1999. Competitive exclusion and coexistence of multiple strains in an SIS STD models. SIAM J. Appl. Math. 59, 1790-1811.
10. Centers for Disease Control and Prevention, Content Reviewed: May 2004. CDC Fact Sheet. Genital HPV Infection. Technical Update: December 2, 2004. Centers for Disease Control Web site. Available at: http://www.cdc.gov/std/HPV/ hpv.pdf. Accessed April 2007.
11. 0 in models for infectious diseases in heterogeneous populations. J. Math. Biol. 28, 503-522.
12. Food and Drug Administration (FDA), 2006. FDA Licenses Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil) for the Prevention of Cervical Cancer and Other Diseases in Females Caused by Human Papillomavirus Product Approval Information, http://www.fda.gov/cder/Offices/ OODP/whatsnew/gardasil.htm. Accessed April 11, 2007.
13. Dunne, E., Unger, E., Sternberg, M., McQuillan, G., Swan, D., Patel, S., Markowitz, L., 2007. Prevalence of HPV infection among females in the United States. JAMA 297, 813-819.
14. Elbasha, E., 2006. Impact of prophylactic vaccination against human papillomavirus infection. Contemp. Math. 410, 113-127.
15. Elbasha, E., Dasbach, E., Insinga, R., 2007. Model for assessing human papillomavirus vaccination strategies. Emerg. Infect. Dis. 13, 28-41.
16. Esteva, L., Vargas, C., 1998. Analysis of a dengue disease transmission model. Math. Biosci. 150, 131-151.
17. Fraser, C., Tomassini, T., Xi, L., Golm, G., Watson, M., et al., 2007. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine 25, 4324-4333.
18. GlaxoSmithKline (GSK). CERVARIX GlaxoSmithKline's Cervical Cancer Candidate Vaccine: Media Backgrounder. Scientific Background For Informational Purposes Only. http://www.gsk.com/media/cervarix-clinical-trials.pdf. Accessed April 11, 2007.
19. Guo, H., Li, M., 2006. Global dynamics of a staged progression model for infectious diseases. Math. Biosci. Eng. 3, 513-525.
20. Harrison, G., 1979. Global stability of predator-prey interactions. J. Math. Biol. 8, 159-171.
21. Harper, D., Franco, E., Wheeler, C., Ferris, D., Jenkins, D., et al., 2004. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364, 1757-1765.
22. Hethcote, H.W., 2000. The mathematics of infectious diseases. SIAM Rev. 42, 599-653.
23. Hughes, J., Garnett, G., Koutsky, L., 2002. The theoretical population level impact of a prophylactic human papillomavirus vaccine. Epidemiology 13, 631-639.
24. Insinga, R., Glass, A., Rush, B., 2004. The healthcare costs of cervical human papillomavirus-related disease. Am. J. Obstet. Gynecol. 191, 1140-120.
25. Iwasa, Y., Michor, F., Nowak, M., 2004. Some basic properties of immune selection. J. Theor. Biol. 229, 179-188.
26. Jansen, K.U., Shaw, A.R., 2004. Human papillomavirus vaccines and prevention of cervical cancer. Annu. Rev. Med. 55, 319-331.
27. Khalil, H., 2002. Nonlinear Systems, 3rd edn. Prentice Hall, New York.
28. Korobeinikov, A., 2004a. Global properties of basic virus dynamics models. Bull. Math. Biol. 66(4), 879-883.
29. Korobeinikov, A., 2004b. Lyapunov functions and global properties for SEIR and SEIS epidemic models. MMB IMA 21, 75-83.
30. Korobeinikov, A., 2006. Lyapunov functions and global stability for SIR and SIRS epidemiological models with non-linear transmission. Bull. Math. Biol. 30, 615-626.
31. Korobeinikov, A., Maini, P.K., 2004. A Lyapunov function and global properties for SIR and SEIR epidemiological models with nonlinear incidence. Math. Biosci. Eng. 1(1), 57-60.
32. Korobeinikov, A., Wake, G.C., 2002. Lyapunov functions and global stability for SIR, SIRS and SIS epidemiological models. Appl. Math. Lett. 15(8), 955-961.
33. Kribs-Zaleta, C., Velasco-Hernández, J., 2000. A simple vaccination model with multiple endemic states. Math. Biosci. 164, 183-201.
34. Li, M., Smith, H., Wang, L., 2001. Global dynamics of an SEIR epidemic model with vertical transmission. SIAM J. Appl. Math. 62, 58-69.
35. Lowry, D., Frazer, I., 2003. Prophylactic human papillomavirus vaccines. J. Natl. Cancer. Inst. Mongr. 31, 111-116.
36. McCluskey, C., 2006. Lyapunov functions for tuberculosis models with fast and slow progression. Math. Biosci. Eng. 3, 603-614.
37. McLean, A., Blower, S., 1993. Imperfect vaccines and herd immunity to HIV. Proc. Roy. Soc. Lond. B 253, 9-13.
38. Moreira, H., Yuquan, W., 1997. Global stability in an SIRI model. SIAM Rev. 39, 496-502.
39. Parkin, D., Bray, F., Ferlay, J., Pisani, P., 2005. Global cancer statistics. Cancer J. Clin. 55, 74-108.
40. Simon, C.P., Jacquez, J.A., 1992. Reproduction numbers and the stability of equilibria of SI models for heterogeneous populations. SIAM J. Appl. Math. 52, 541-576.
41. Tjalma, W.A.A., Arbyn, M., Paavonen, J., Van Waes, T.R., Bogers, J.J., 2004. Prophylactic human papillomavirus vaccines: the beginning of the end of cervical cancer. Int. J. Gynecol. Cancer 14, 751-751.
42. Villa, L.L., Costa, R.L.R., Petta, C.A., Andrade, R.P., Ault, K.A., et al., 2005. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6, 271-78.
43. Villa, L.L., Costa, R.L.R., Petta, C.A., Andrade, R.P., Paavonent, J., et al., 2007. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow up. Br. J. Cancer 95, 1459-1466.